1 / 25

Conflict of Interest Statement:

THE LIPID PANEL What are we missing? Robert St. Amant, MD, FAAFP Diplomate, American Board of Clinical Lipidology Baton Rouge General Medical Director, Lipid Center Womack Heart Center. Conflict of Interest Statement:. Speakers Bureau for the following companies: Abbott Laboratories

yoko
Download Presentation

Conflict of Interest Statement:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. THE LIPID PANELWhat are we missing? Robert St. Amant, MD, FAAFPDiplomate, American Board of Clinical LipidologyBaton Rouge General Medical Director, Lipid CenterWomack Heart Center

  2. Conflict of Interest Statement: • Speakers Bureau for the following companies: • Abbott Laboratories • CardioDx • Kowa/Lilly • Berkeley HeartLab • Clinical Investigator: • CardioDx

  3. Audience Objectives: • Have a better understanding of the standard lipid panel and cardiovascular disease risks. • Be able to discuss the relationship between cholesterol and lipoproteins and why patients with normal lipid panels have cardiovascular events. • Explore more advanced cholesterol, biomarker, and genetic tests available to enhance cardiovascular disease risk assessment.

  4. The Lipid Panel • Total Cholesterol • Triglycerides • HDLc • LDLc …….What’s missing?

  5. Cholesterol • Cell structure • Sex hormones • Bile acids • Vitamin D

  6. Total Cholesterol • Structure • Sources • NCEP goal?

  7. Triglycerides • Structure • Sources • Purpose • NCEP target

  8. HDL cholesterol • Structure • Sources • Purpose • NCEP target

  9. LDL cholesterol • Structure • Sources • Purpose • Primary NCEP ATPIII goal

  10. Non-HDL Cholesterol • What??? • “New” 5th lipid fraction • ALL BAD cholesterol, not just LDLc. • Atherogenic lipoprotein particles • Residual risk • Secondary NCEP goal: 30mg/dL above LDLc goal

  11. NCEP ATPIII LDLc Goals: • CHD/CHD risk equivalents • Moderate CHD risk • Low CHD risk • Non-HDLc goal • TG primary goal

  12. CVD Risk Factors • Smoking • Age >/=45M, 55F • HPT >/=140/90 • Low HDL <40* • Family Hx CAD • Age <55M, <65F * HDL >/= 60 is a negative risk factor

  13. Lipoproteins • Insolubility • Lipid trafficking vehicles • ApoA and ApoB • Interheart Study • ApoB/ApoA

  14. ApoB Lipoproteins • Size • Composition • Atherogenic • Discordance • LDLc, LDLp, MIs

  15. ApoA Lipoproteins • Protective • HDL cholesterol • Functions • Quantity vs Quality • HDLc vs HDLp • Protein Cargo

  16. Atherosclerosis • Complex process • Progressive • Inflammatory • Endothelial dysfunction • Atheroma burden • Plaque rupture

  17. Risk Factors • Lifestyles • Non-modifiable • Modifiable • Insulin resistance

  18. Insulin Resistance • Definition • Diagnosis • Prevalence • 70% of MIs • Treatment

  19. Metabolic Syndrome • 5 Criteria • 3/5 = diagnosis • 1/3 adults • Screening • CAD & DM risks

  20. Looking Beyond the Lipid Panel • Using Selected Biomarkers • Not for low risk patients • Diligent risk evaluation • Residual risk on statin therapy

  21. Advanced Cholesterol Testing • Beyond the lipid panel • Not for everyone • Intermediate and high risk patients • Affordable • Part of “What’s Missing?”

  22. Lp(a) • LDL particle with an apo(a) protein • Very atherogenic • Disrupts process of fibrinolysis • MI/stroke risk • CV events with normal lipids

  23. Lp-PLA2 • Enzyme on LDLp • Rapid plaque formation • Prone to rupture • MI / stroke risk • Treat BP/meds

  24. SLCO1B1 Genotype • Gene variation for OATP • Increased level statin drug • Myalgia risk • Statin “intolerance”

  25. Thank You!Questions?

More Related